Close

Flexion Therapeutics (FLXN) Announces Zilretta Trial in T2D Patients with Knee OA Met Primary Endpoint

Go back to Flexion Therapeutics (FLXN) Announces Zilretta Trial in T2D Patients with Knee OA Met Primary Endpoint